A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients

Summary

This is a phase III randomized, double blinded, placebo-controlled multi-center study to assess the efficacy and safety of aerosolized Novaferon for the treatment of asymptomatic or mildly patients infected with SARS-CoV-2.

Timeline

Start

2021-08-31

Primary completion

2022-04-30

Completion

2022-08-31

Drugs

Indications